CCP
HUMA icon

Clough Capital Partners’s Humacyte HUMA Stock Holding History

Clough Capital Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-240,934
Closed -$504K – 131
2025
Q2 		$504K Buy
+240,934
New +$463K 0.05% 109
2025
Q1 		– Sell
-104,400
Closed -$527K – 125
2024
Q4 		$527K Sell
104,400
-74,368
-42% -$368K 0.06% 102
2024
Q3 		$972K Buy
+178,768
New +$1.18M 0.1% 101
2024
Q2 		– Sell
-156,263
Closed -$486K – 127
2024
Q1 		$486K Buy
156,263
+27,008
+21% +$90.8K 0.05% 108
2023
Q4 		$367K Buy
129,255
+49,946
+63% +$128K 0.04% 159
2023
Q3 		$232K Buy
+79,309
New +$262K 0.02% 178

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clough Capital Partners's HUMA Position: Q3 2025 in Review

Clough Capital Partners sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 240,934 shares — an estimated $504K sold.

Clough Capital Partners first reported a position in HUMA in Q3 2023 and held it in 6 quarters. The position peaked at $972K in Q3 2024. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • Clough Capital Partners reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • Clough Capital Partners sold 240,934 Humacyte shares in Q3 2025, an estimated $504K.
  • Clough Capital Partners first reported a position in Humacyte in Q3 2023 and held it in 6 quarters.
  • Clough Capital Partners's Humacyte position peaked at $972K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Clough Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.